Invasive Bladder Cancer Clinical Trial
— mpMRIOfficial title:
Multiparametric Magnetic Resonance Imaging Performance in Detection of Occult Muscle Invasion in Urinary Bladder Cancer
NCT number | NCT05783271 |
Other study ID # | universty |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 2, 2023 |
Est. completion date | March 31, 2025 |
The purpose of this study is to assess the performance of multiparametric MRI in detection of occult muscle invasion in urinary bladder cancer
Status | Recruiting |
Enrollment | 58 |
Est. completion date | March 31, 2025 |
Est. primary completion date | March 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 58 cases of patients who suspected to have cancer urinary bladder by clinical, histopathological examination and radiological imaging. All age groups . Both sex Exclusion Criteria: patient with high renal chemistry. Patient with contraindications to MRI as pacemaker and cochlear implants. - |
Country | Name | City | State |
---|---|---|---|
Egypt | Assuit university | Assuit |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Al Johi RS, Seifeldein GS, Moeen AM, Aboulhagag NA, Moussa EM, Hameed DA, Imam HM. Diffusion weighted magnetic resonance imaging in bladder cancer, is it time to replace biopsy? Cent European J Urol. 2018;71(1):31-37. doi: 10.5173/ceju.2017.1427. Epub 2017 Jan 16. — View Citation
Caglic I, Panebianco V, Vargas HA, Bura V, Woo S, Pecoraro M, Cipollari S, Sala E, Barrett T. MRI of Bladder Cancer: Local and Nodal Staging. J Magn Reson Imaging. 2020 Sep;52(3):649-667. doi: 10.1002/jmri.27090. Epub 2020 Feb 29. — View Citation
Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D'Andrea D, Messina E, Pisciotti LM, De Berardinis E, Sciarra A, Panebianco V. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol. 2022 Jul;40(7):1617-1628. doi: 10.1007/s00345-022-03969-6. Epub 2022 Mar 16. — View Citation
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146. — View Citation
Gmeiner J, Garstka N, Helbich TH, Shariat SF, Baltzer PA. Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC? Eur J Radiol. 2021 Sep;142:109829. doi: 10.1016/j.ejrad.2021.109829. Epub 2021 Jun 24. — View Citation
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598. — View Citation
Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol. 2019 Dec;92(1104):20190401. doi: 10.1259/bjr.20190401. Epub 2019 Oct 8. — View Citation
Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone MD, Del Monte M, Carano D, Gallucci M, Catto J, Catalano C. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol. 2017 Sep;27(9):3759-3766. doi: 10.1007/s00330-017-4758-3. Epub 2017 Feb 8. — View Citation
Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 Sep;74(3):294-306. doi: 10.1016/j.eururo.2018.04.029. Epub 2018 May 10. — View Citation
Rabie E, Faeghi F, Izadpanahi MH, Dayani MA. Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Staging of Bladder Cancer. J Clin Diagn Res. 2016 Apr;10(4):TC01-5. doi: 10.7860/JCDR/2016/17596.7690. Epub 2016 Apr 1. — View Citation
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020 Mar 13;8(1):15. doi: 10.3390/medsci8010015. — View Citation
Shelmerdine SC, Lorenzo AJ, Gupta AA, Chavhan GB. Pearls and Pitfalls in Diagnosing Pediatric Urinary Bladder Masses. Radiographics. 2017 Oct;37(6):1872-1891. doi: 10.1148/rg.2017170031. — View Citation
Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, Chen J, Luo J, Chen L, Guo Y. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019 Jun;291(3):668-674. doi: 10.1148/radiol.2019182506. Epub 2019 Apr 23. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the Performance of multiparametric magnetic resonance imaging in detection of occult muscle invision in urinary bladder cancer | in this cohort study ,we will examine patients refered to radiology department Assuit university hospital by mpMRI from 31/3/223 untill 1/1/2024 then all data will be regrouped to evaluate the accuracy of each separate sequence and mp-MRI in distinguishing non muscle invasive from muscle invasive tumours,with VI-RADS score application and comparison with pathological findings,then interobserver agreement for detection of muscle invasion according to mp-MRI and VI-RADS scoring system findings will be calculated. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Completed |
NCT02924480 -
Intravenous Lidocaine for Cystectomy Procedures
|
N/A | |
Active, not recruiting |
NCT03702179 -
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
|
Phase 2 | |
Completed |
NCT03862105 -
Testing the Utilization of a Mobile Health App for Patients Undergoing Cystectomy Surgery for Bladder Cancer
|
N/A | |
Recruiting |
NCT02560636 -
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02030574 -
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
|
Phase 2 | |
Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04134000 -
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
|
Phase 1 | |
Terminated |
NCT03498196 -
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04523038 -
Nordic Cystectomy Study II - Albumin
|
||
Recruiting |
NCT04523025 -
Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)
|
||
Withdrawn |
NCT01922232 -
MRI and Bladder Cancer Chemotherapy
|
N/A | |
Completed |
NCT03514888 -
HIPEC After Radical Cystectomy for High Risk Bladder Cancer
|
N/A |